Influenza, Meningitis
Conditions
Keywords
immunogenicity, safety, group A, C polysaccharide meningitis, type b haemophilus Influenza
Brief summary
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections. The infection of haemophilus is a major cause of morbidity and mortality in infants and children. At present, the developed conjugant Hib vaccine is proved to be safe and effective. Because Hib vaccine can prevent meningitis, pneumonia, epiglottis inflammation and other serious infection caused by Hib bacteria, the WHO suggested that Hib vaccine should be included in the infant's normal immune programming. Since the use of meningitis aureus polysaccharide vaccine, incidence of a disease in recent years is declined and maintain to the level of 0.5 per 1/100 thousand. But meningitis aureus polysaccharide vaccine with a relatively poor immune response in the infants under the age of two, and the remaining 60% with a low antibody level and a short duration. The immunogenicity and safety of this vaccine has been proved in older children aged 6-23 months and 2-5 years. And in the phase I study which was conducted in February, 2012, the safety profile of this vaccine is proved to be acceptable in infants aged 3-5 months. The phase III study is aimed to further evaluate the safety and the immunization of the vaccine. The objective of this study is to evaluate the safety of the group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine.
Interventions
BIOLOGICALA+C+hib Conjugate Vaccine
The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
BIOLOGICALPlacebo
Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
BIOLOGICALA+C Vaccine
The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
BIOLOGICALHib vaccine
The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
Sponsors
Royal (Wuxi) Biological Co., LTD
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Months to 5 Months
Healthy volunteers
No
Inclusion criteria
* Healthy subjects aged 3 to 5 months, normal intelligence. * The subjects' guardians are able to understand and sign the informed consent. * Healthy subjects confirmed by medical history questioning, physical examination and clinical decision and in accordance with vaccination requirements of the investigational vaccine. * Subjects who can comply with the requirements of the clinical trial program according to the researcher's views. * Subjects who have never received group A, C polysaccharide meningococcal vaccine and type b haemophilus Influenzal vaccine. * Subjects with temperature\<=37°C on axillary setting.
Exclusion criteria
for the first vaccination: * Subject who has a medical history of Meningitis; * Subject who has a medical history of any of the following: allergies, seizures, epilepsy, encephalopathy history and so on; * Subject who is allergic with tetanus toxoid components; * Subject suffering from thrombocytopenia or other coagulation disorder may lead to contraindication to intramuscular injection; * Subject who has a history of allergic reactions; * Any known immunological dysfunction; * Had received gamma globulin or immune globulin, in the past two weeks * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws * Any acute infections in last 7 days * Any prior administration of immunodepressant or corticosteroids in last 6month * Any prior administration of other research medicines in last 1 month * Any prior administration of attenuated live vaccine in last 28 days * Any prior administration of subunit or inactivated vaccines in last 14 days, such as pneumococcal vaccine * Subject suffering from congenital malformations, developmental delay or serious chronic disease; * Any acute infections * Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The seroconversion rate of antibody against group A, C polysaccharide meningitis in infants aged 3-5 months | 4 weeks (28±3 days) after the infant series | the seroconversion rate of antibody against group A, C polysaccharide meningitis in infants aged 3-5 months when measured 4 weeks (28±3 days) after the infant series (three doses, 28 day apart). |
| The seroconversion rate of antibody against type b haemophilus influenza in infants aged 3-5 months | 4 weeks (28±3 days) after the infant series | the seroconversion rate of antibody against type b haemophilus Influenza in infants aged 3-5 months when measured 4 weeks (28±3 days) after the infant series (three doses, 28 day apart) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| adverse reactions after the third vaccination in infants aged 3-5 months | 7 days after the third vaccination | adverse reactions of the investigational vaccines in healthy infants aged 3-5 months for 7 days after the third vaccination |
| adverse reactions after the first vaccination in infants aged 3-5 months | 7 days after the first vaccination | adverse reactions of the investigational vaccines in healthy infants aged 3-5 months for 7 days after the first vaccination |
| GMT of antibody against type b haemophilus Influenza in serum in infants aged 3-5 months | 4 weeks (28±3 days) after the infant series | GMT of antibody against type b haemophilus Influenza in infants aged 3-5 months 4 weeks (28±3 days) after the infant series (three doses, 28 day apart) |
| GMT of antibody against group A, C polysaccharide meningitis in infants aged 3-5 months | 4 weeks (28±3 days) after the infant series | GMT of antibody against group A, C polysaccharide meningitis in infants aged 3-5 months 4 weeks (28±3 days) after the infant series (three doses, 28 day apart) |
| adverse reactions after the second vaccination in infants aged 3-5 months | 7 days after the second vaccination | adverse reactions of the investigational vaccines in healthy infants aged 3-5 months for 7 days after the second vaccination |
Countries
China
Outcome results
None listed